Nyxoah is a healthtech company developing neuromodulation-based therapeutic solutions for sleep disordered breathing conditions.
Nyxoah is focused on the development and commercialisation of innovative solutions and services for the treatment of Obstructive Sleep Apnea (OSA).
Nyxoah was founded in 2009 by Robert Taub. The company is headquartered in Mont-Saint-Guibert, Walloon Brabant, Belgium.
Nyxoah’s lead solution platform is based on the Genio® system, a validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Nyxoah’s therapy consists of a tiny neurostimulator implanted in the chin area in a discrete and minimally invasive surgery. The system which is powered by an external miniaturized battery is placed under the chin and stimulates the tongue nerve. This maintains the upper airway open throughout the night.
Nyxoah is backed by Cochlear Limited, ResMed and others. The company raised €25M (nearly $28M) in a latest private financing round on Feb 12, 2020. This brings Nyxoah's total funding to €66M to date.